Male Hypogonadism Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Male Hypogonadism Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Summary

GlobalData, the industry analysis specialist, has released its new report, “Male Hypogonadism Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Male Hypogonadism Therapeutics market. The report identifies the key trends shaping and driving the global Male Hypogonadism Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Male Hypogonadism Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Male Hypogonadism Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Male Hypogonadism Therapeutics market revenues data from 2006 to 2010, forecast for nine years to 2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Male Hypogonadism Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Male Hypogonadism Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Male Hypogonadism Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Male Hypogonadism Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Male Hypogonadism Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Male Hypogonadism Therapeutics market landscape? – Identify, understand and capitalize. SHOW LESS READ MORE >

1
1

1.1 List of Tables
1.2 List of Figures
2 Male Hypogonadsim Therapeutics - Introduction
2.1 Disease Overview
2.2 Epidemiology
2.2.1 The US
2.2.2 The UK
2.2.3 Germany
2.2.4 France
2.2.5 Italy
2.2.6 Spain
2.2.7 Japan
2.2.8 Mortality
2.2.9 Pharma-economic Burden
2.3 Etiology
2.4 Pathophysiology
2.5 Signs and Symptoms
2.6 Diagnosis
2.6.1 Medical History
2.6.2 Diagnostic Criteria
2.7 Treatment and Management Options
2.7.1 Testosterone Replacement Therapy
2.8 Referral Pathway
2.9 GlobalData Pipeline Report Guidance
3 Male Hypogonadism Therapeutics - Market Characterization
3.1 Male Hypogonadism Therapeutics Market Size (2006-2011) - Global
3.2 Male Hypogonadism Therapeutics Market Forecast (2011-2019) - Global
3.3 Male Hypogonadism Therapeutics Market Size (2006-2011) - The US
3.4 Male Hypogonadism Therapeutics Market Forecast (2011-2019) - The US
3.5 Male Hypogonadism Therapeutics Market Size (2006-2011) - France
3.6 Male Hypogonadism Therapeutics Market Forecast (2011-2019) - France
3.7 Male Hypogonadism Therapeutics Market Size (2006-2011) - Germany
3.8 Male Hypogonadism Therapeutics Market Forecast (2011-2019) - Germany
3.9 Male Hypogonadism Therapeutics Market Size (2006-2011) - Italy
3.10 Male Hypogonadism Therapeutics Market Forecast (2011-2019) - Italy
3.11 Male Hypogonadism Therapeutics Market Size (2006-2011) - Spain
3.12 Male Hypogonadism Therapeutics Market Forecast (2011-2019) - Spain
3.13 Male Hypogonadism Therapeutics Market Size (2006-2011) - The UK
3.14 Male Hypogonadism Therapeutics Market Forecast (2011-2019) - The UK
3.15 Male Hypogonadism Therapeutics Market Size (2006-2011) - Japan
3.16 Male Hypogonadism Therapeutics Market Forecast (2011-2019) - Japan
3.17 Drivers and Barriers for the Male Hypogonadism Therapeutics Market
3.17.1 Drivers for the Male Hypogonadism Therapeutics Market
3.17.2 Barriers for the Male Hypogonadism Therapeutics Market
3.18 Opportunity and Unmet Need
3.19 Key Takeaway
4 Male Hypogonadism Therapeutics - Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profiles for the Major Marketed Products in the Male Hypogonadism Therapeutics Market
4.3.1 AndroGel (testosterone gel)
4.3.2 Fortesta (testosterone gel)
4.3.3 Testim (testosterone gel)
4.3.4 Axiron (testosterone topical solution)
4.3.5 Striant (testosterone buccal system)
4.4 Key Takeaway
5 Male Hypogonadism Therapeutics - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Male Hypogonadism Therapeutics Pipeline - Pipeline by Phases of Development
5.3.1 Male Hypogonadism Therapeutics - Filed Pipeline
5.3.2 Male Hypogonadism Therapeutics - Phase III Pipeline
5.3.3 Male Hypogonadism Therapeutics - Phase II Pipeline
5.3.4 Male Hypogonadism Therapeutics - Phase I Pipeline
5.3.5 Male Hypogonadism Therapeutics Market - Discovery Pipeline
5.3.6 Technology Trends Analytic Framework
5.4 Male Hypogonadism Therapeutics Market - Pipeline by Mechanism of Action
5.5 Male Hypogonadism Therapeutics - Promising Drugs under Clinical Development
5.6 Molecule Profiles for Promising Drugs under Clinical Development
5.6.1 Aveed/Nebido (testosterone undecanoate injection)
5.6.2 Bio-T-Gel (transdermal testosterone gel)
5.6.3 OriTex (oral testosterone undecanoate)
5.6.4 Compleo TRT (testosterone intranasal gel)
5.7 Key Takeaway
6 Male Hypogonadism Therapeutics - Clinical Trials Mapping
6.1 Clinical Trials by Region/Country (The US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Prominent Sponsors
6.5 Top Companies Participating in Male Hypogonadism Therapeutics Clinical Trials
7 Male Hypogonadism Therapeutics - Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 Male Hypogonadism Therapeutics: Implications for Future Market Competition
8 Male Hypogonadism Therapeutics - Future Players
8.1 Introduction
8.2 Company Profiles
8.3 Endo Pharmaceuticals
8.3.1 Company Overview
8.3.2 Financial Performance
8.3.3 Male Hypogonadism Pipeline Product
8.4 Teva
8.4.1 Company Overview
8.4.2 Financial Performance
8.4.3 Male Hypogonadism Pipeline Product
8.5 Clarus Therapeutics
8.5.1 Company Overview
8.5.2 Financial Performance
8.5.3 Male Hypogonadism Pipeline Product
8.6 Trimel Pharmaceuticals
8.6.1 Company Overview
8.6.2 Financial Performance
8.6.3 Male Hypogonadism Pipeline Product
9 Appendix
9.1 Market Definitions
9.2 Abbreviations
9.3 Methodology
9.3.1 Coverage
9.3.2 Secondary Research
9.3.3 Forecasting
9.3.4 Primary Research
9.3.5 Expert Panel Validation
9.4 Contact Us
9.5 Disclaimer
9.6 Bibliography

1.1 List of Tables
Table 1: Male Hypogonadism, Alternative Names
Table 2: Male Hypogonadism, Classification and Hormone Levels
Table 3: Causes of Primary Male Hypogonadism and Secondary Male Hypogonadism
Table 4: Physiological Effects of Testosterone in Adult Males
Table 5: Male Hypogonadism, Signs and Symptoms
Table 6: Formulations for Testosterone Replacement
Table 7: Male Hypogonadism Therapeutics Market, Global, Revenue ($m), 2006-2011
Table 8: Male Hypogonadism Therapeutics Market, Global, Forecast ($m), 2011-2019
Table 9: Male Hypogonadism Therapeutics Market, The US, Revenue ($m), 2006-2011
Table 10: Male Hypogonadism Therapeutics Market, The US, Forecasts ($m), 2011-2019
Table 11: Male Hypogonadism Therapeutics Market, France, Revenue ($m), 2006-2011
Table 12: Male Hypogonadism Therapeutics Market, France, Forecasts ($m), 2011-2019
Table 13: Male Hypogonadism Therapeutics Market, Germany, Revenue ($m), 2006-2011
Table 14: Male Hypogonadism Therapeutics Market, Germany, Forecasts ($m), 2011-2019
Table 15: Male Hypogonadism Therapeutics Market, Italy, Revenue ($m), 2006-2011
Table 16: Male Hypogonadism Therapeutics Market, Italy, Forecasts ($m), 2011-2019
Table 17: Male Hypogonadism Therapeutics Market, Spain, Revenue ($m), 2006-2011
Table 18: Male Hypogonadism Therapeutics Market, Spain, Forecasts ($m), 2011-2019
Table 19: Male Hypogonadism Therapeutics Market, The UK, Revenue ($m), 2006-2011
Table 20: Male Hypogonadism Therapeutics Market, The UK, Forecasts ($m), 2011-2019
Table 21: Male Hypogonadism Therapeutics Market, Japan, Revenue ($m), 2006-2011
Table 22: Male Hypogonadism Therapeutics Market, Japan, Forecasts ($m), 2011-2019
Table 23: Mean Testosterone Concentrations (Cavg and Cmax) by Final Dose on Day 112 and Day 364
Table 24: Adverse Reactions Reported in >2% of Male Hypogonadal Patients in the 182-Day, Double-Blind Period of AndroGel 1.62% Clinical Trial
Table 25: Adverse Drug Reactions of Fortesta, Reported in >1% Hypogonadal Male Patients in the US Phase III Clinical Trial of Fortesta
Table 26: Incidence of Adverse Events Judged Possibly, Probably or Definitely Related to Use of Testim in the Controlled Clinical Trial
Table 27: Adverse Reactions Seen With the Use of Axiron on 120th Day of the Clinical Trial
Table 28: Incidences of Adverse Events Possibly, Probably or Definitely Related to Use of Striant in Study 1
Table 29: Male Hypogonadism Therapeutics, Filed Pipeline, 2011
Table 30: Male Hypogonadism Therapeutics, Phase III Pipeline, 2011
Table 31: Male Hypogonadism Therapeutics, Phase II Pipeline, 2011
Table 32: Male Hypogonadism Therapeutics, Phase I Pipeline, 2011
Table 33: Male Hypogonadism Therapeutics, Discovery, 2011
Table 34: Male Hypogonadism Therapeutics, Most Promising Drugs Under Clinical Development, 2011
Table 35: Male Hypogonadism Therapeutics Market, Clinical Trials by Country, 2011
Table 36: Male Hypogonadism Therapeutics Market Therapeutics, Clinical Trials by Phase, 2011
Table 37: Male Hypogonadism Therapeutics, Clinical Trials by Status, 2011
Table 38: Male Hypogonadism Therapeutics, Prominent Sponsors, 2011
Table 39: Male Hypogonadism Therapeutics, Top Companies Participating in Male Hypogonadism Therapeutics Clinical Trials, 2011
Table 40: Endo Pharmaceuticals, Male Hypogonadism Pipeline Products, 2011
Table 41: Teva, Male Hypogonadism Pipeline Products, 2011
Table 42: Clarus Therapeutics, Male Hypogonadism Pipeline Products, 2011
Table 43: Trimel Pharmaceuticals, Male Hypogonadism Pipeline Products, 2011

1.2 List of Figures
Figure 1: Basic Physiology of Testosterone
Figure 2: The Hypothalamic Pituitary Gonadal Axis is Regulated by a Negative Feedback Mechanism
Figure 3: Male Hypogonadism, Diagnosis Algorithm
Figure 4: Male Hypogonadism, General Practitioner/Pre-referral Pathway 2011
Figure 5: Male Hypogonadism, Endocrinologist, During/Post-referral Pathway 2011
Figure 6: Male Hypogonadism Therapeutics Market, Global, Revenue ($m), 2006-2011
Figure 7: Male Hypogonadism Therapeutics Market, Global, Forecast ($m), 2011-2019
Figure 8: Male Hypogonadism Therapeutics Market, The US, Revenue ($m), 2006-2011
Figure 9: Male Hypogonadism Therapeutics Market, The US, Forecast ($m), 2011-2019
Figure 10: Male Hypogonadism Therapeutics Market, France, Revenue ($m), 2006-2011
Figure 11: Male Hypogonadism Therapeutics Market, France, Forecast ($m), 2011-2019
Figure 12: Male Hypogonadism Therapeutics Market, Germany, Revenue ($m), 2006-2011
Figure 13: Male Hypogonadism Therapeutics Market, Germany, Forecast ($m), 2011-2019
Figure 14: Male Hypogonadism Therapeutics Market, Italy, Revenue ($m), 2006-2011
Figure 15: Male Hypogonadism Therapeutics Market, Italy, Forecast ($m), 2011-2019
Figure 16: Male Hypogonadism Therapeutics Market, Spain, Revenue ($m), 2006-2011
Figure 17: Male Hypogonadism Therapeutics Market, Spain, Forecast ($m), 2011-2019
Figure 18: Male Hypogonadism Therapeutics Market, The UK, Revenue ($m), 2006-2011
Figure 19: Male Hypogonadism Therapeutics Market, The UK, Forecast ($m), 2011-2019
Figure 20: Male Hypogonadism Therapeutics Market, Japan, Revenue ($m), 2006-2011
Figure 21: Male Hypogonadism Therapeutics Market, Japan, Forecast ($m), 2011-2019
Figure 22: Opportunity and Unmet Need in the Male Hypogonadism Therapeutics Market, 2011
Figure 23: Male Hypogonadism Therapeutics, Strategic Competitor Assessment, 2011
Figure 24: Male Hypogonadism Therapeutics, Pipeline by Phase of Development, 2011
Figure 25: Male Hypogonadism Therapeutics, Technology Trends Analytics Framework, 2011
Figure 26: Male Hypogonadism Therapeutics, Technology Trends Analytics Framework - Description, 2011
Figure 27: Male Hypogonadism Therapeutics, Pipeline by Mechanism of Action, 2011
Figure 28: Male Hypogonadism Therapeutics Market, Clinical Trials by Country, 2011
Figure 29: Male Hypogonadism Therapeutics, Clinical Trials by Phase, 2011
Figure 30: Male Hypogonadism Therapeutics, Clinical Trials by Status, 2011
Figure 31: Male Hypogonadism Therapeutics Market, Overall Sponsors, 2011
Figure 32: Male Hypogonadism Therapeutics, Prominent Sponsors, 2011
Figure 33: Male Hypogonadism Therapeutics, Top Companies Participating in Male Hypogonadism Therapeutics Clinical Trials, 2011
Figure 34: Male Hypogonadism Therapeutics Market, Drivers and Restraints, 2011
Figure 35: Implications for Future Market Competition in the Male Hypogonadism Market, 2011
Figure 36: Male Hypogonadism Therapeutics Market, Pipeline by Company, 2011
Figure 37: GlobalData Market Forecasting Model

GlobalData, the industry analysis specialist, has released its new report, “Male Hypogonadism Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global male hypogonadism therapeutics market. The report identifies the key trends shaping and driving the global male hypogonadism therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global male hypogonadism therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Male Hypogonadism Therapeutics Market is Forecast to Show Moderate Growth until 2019

GlobalData estimates that the male hypogonadism therapeutics market was valued at $1,584m in 2011, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 3.1% over the next eight years, to reach $2,015m by 2019. This projected market growth is primarily attributed to increasing the elderly population in the US, Japan and in other European countries and the expected launch of Aveed (testosterone undecanoate injection) and Bio-T-Gel (testosterone transdermal gel) in 2012, and OriTex (testosterone undecanoate oral) in 2016 in the US. However the high growth (11.7%) achieved during 2006-2011 is not expected to continue until 2019 because of the patent expiry of the two major drugs – Axiron (testosterone topical solution) in 2017and Fortesta (testosterone gel) in 2018 in the US. The current competitive landscape for the treatment of male hypogonadism consists of five approved testosterone replacement therapies and two commonly prescribed generics. The five approved testosterone replacement therapies for the treatment of male hypogonadism are AndroGel (testosterone gel), Fortesta, Testim (testosterone gel), Striant (testosterone buccal system) and Axiron. The two commonly prescribed generics for the treatment of male hypogonadism are testosterone enanthate injection and testosterone transdermal patch.

Male Hypogonadism Therapeutics Market, Global, Market Revenue ($m), 2006–2019

Source: GlobalData, International Journal of Clinical Practice 2006. Journal of Clinical Endocrinology and Metabolism 2004. The Centre for Men's Health 2011, the UK. Carruthers M, Time for international action on treating testosterone deficiency syndrome. Aging Male 2009; 12 (1):21-8. Heinemann LA. Aging males' symptoms scale: a standardized instrument for the practice. J Endocrinol Invest 2005; 28:34–38.

Endo Pharmaceuticals
Teva 65
Clarus Therapeutics
Trimel Pharmaceuticals